— BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B — — BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natural compound scaffolds — VANCOUVER, British Columbia, April 19, 2023 (GLOBE NEWSWIRE) — Bright Minds Biosciences…
Source